Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences: The Bank of...
May 05, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones

—Q1 2022 ORLADEYO net revenue of $49.7 million— —ORLADEYO net revenue in 2022 expected to be no less than $250 million— —Company provides update on BCX9930 investigation— RESEARCH TRIANGLE...
May 04, 2022 16:15 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
April 27, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

RESEARCH TRIANGLE PARK, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the European Medicines Agency (EMA) has granted access to the Priority...
April 21, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Report First Quarter 2022 Financial Results on May 5

RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2022 financial results...
April 11, 2022 08:30 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21st Annual Needham Virtual...
April 08, 2022 09:15 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Pauses Enrollment in BCX9930 Clinical Trials

RESEARCH TRIANGLE PARK, N.C., April 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has paused enrollment in clinical trials with BCX9930...
April 05, 2022 07:15 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...
March 03, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 42nd Annual Health Care...
March 02, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 02, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...